公开(公告)号：US09605070B2

公开(公告)日：2017-03-28

申请号：US14610837

申请日：2015-01-30

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6893

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

公开(公告)号：US20180207273A1

公开(公告)日：2018-07-26

申请号：US15747326

申请日：2016-07-28

Applicant: Glenn Dranoff ,  Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu ,  Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Glenn Dranoff ,  Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/39566 ,  A61K39/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/94 ,  A61K2300/00

Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

公开(公告)号：US20170190777A1

公开(公告)日：2017-07-06

申请号：US15462585

申请日：2017-03-17

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6893

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

公开(公告)号：US11459390B2

公开(公告)日：2022-10-04

申请号：US15543688

申请日：2016-01-15

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Hilmar Erhard Ebersbach ,  David Glass ,  Thomas Huber ,  Julia Jascur ,  Carl H. June ,  Jihyun Lee ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Avery D. Posey ,  Huijuan Song ,  Yongqiang Wang ,  Lai Wei ,  Qilong Wu ,  Qiumei Yang ,  Jiquan Zhang

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K35/17 ,  C07K16/30 ,  A61P35/00 ,  A61P35/02 ,  A61K48/00 ,  C12N15/86 ,  A61K35/12

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

公开(公告)号：US10981990B2

公开(公告)日：2021-04-20

申请号：US16841029

申请日：2020-04-06

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  The Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: A61K39/395 ,  C07K16/28 ,  G01N33/574 ,  A61K45/06 ,  G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

公开(公告)号：US10851166B2

公开(公告)日：2020-12-01

申请号：US15689163

申请日：2017-08-29

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hilmar Erhard Ebersbach ,  Thomas Huber ,  Julia Jascur ,  Celeste Richardson ,  Reshma Singh ,  Huijuan Song ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  A61K39/395 ,  A61K31/436 ,  C07K14/705 ,  A61K35/28 ,  A61K31/711 ,  A61K38/17 ,  A61K45/06 ,  C07K14/715 ,  A61K48/00 ,  A61K39/00 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

公开(公告)号：US09938342B2

公开(公告)日：2018-04-10

申请号：US15466128

申请日：2017-03-22

Applicant: Novartis AG

Inventor： Franco E. Di Padova ,  Thomas Huber ,  Jean-Michel Rene Rondeau

IPC: C12P21/02 ,  C07K16/24 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12N15/64 ,  C12N5/07 ,  C07K14/54 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for the antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

公开(公告)号：US20170198041A1

公开(公告)日：2017-07-13

申请号：US15432819

申请日：2017-02-14

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

公开(公告)号：US20170198035A1

公开(公告)日：2017-07-13

申请号：US15466128

申请日：2017-03-22

Applicant: Novartis AG

Inventor： Franco E. Di Padova ,  Thomas Huber ,  Jean-Michel Rene Rondeau

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in viva The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

公开(公告)号：US12077580B2

公开(公告)日：2024-09-03

申请号：US16862776

申请日：2020-04-30

Applicant: Novartis AG

Inventor： Franco E. Di Padova ,  Thomas Huber ,  Jean-Michel Rene Rondeau

IPC: A61K39/395 ,  C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.